Free tool
FAERS Monitor: Daraprim
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 008578 or its brand name (Daraprim, Pyrimethamine). Reports on generic versions are filed under their own applications.
Reports
1,270
Serious
980
77% of reports
Hospitalization
540
Death reported
221
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use164
- nausea134
- vomiting101
- pancytopenia91
- drug ineffective73
- neutropenia72
- pyrexia64
- headache63
- death50
- dizziness50
- acute kidney injury49
- rash49
- cerebral toxoplasmosis47
- diarrhoea47
- thrombocytopenia43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 13 |
| 2007 | 16 |
| 2008 | 23 |
| 2009 | 27 |
| 2010 | 24 |
| 2011 | 19 |
| 2012 | 18 |
| 2013 | 21 |
| 2014 | 29 |
| 2015 | 26 |
| 2016 | 77 |
| 2017 | 85 |
| 2018 | 128 |
| 2019 | 103 |
| 2020 | 136 |
| 2021 | 107 |
| 2022 | 125 |
| 2023 | 79 |
| 2024 | 72 |
| 2025 | 57 |
| 2026 | 47 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,889 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral toxoplasmosisSignal | 47 | 878.4 | 658.5 | 38,290 |
| pancytopeniaSignal | 91 | 27.0 | 22.2 | 2,256 |
| neutropeniaSignal | 72 | 8.8 | 7.0 | 491 |
| thrombocytopeniaSignal | 43 | 6.4 | 4.7 | 190 |
| acute kidney injurySignal | 49 | 5.3 | 4.0 | 168 |
| vomitingSignal | 101 | 3.6 | 3.0 | 187 |
| off label useSignal | 164 | 3.1 | 2.7 | 242 |
| pyrexiaSignal | 64 | 3.1 | 2.4 | 88 |
| nauseaSignal | 134 | 2.8 | 2.4 | 160 |
| rash | 49 | 1.9 | 1.4 | 19 |
| headache | 63 | 1.7 | 1.3 | 17 |
| dizziness | 50 | 1.7 | 1.3 | 13 |
| diarrhoea | 47 | 1.2 | 0.9 | 1 |
| death | 50 | 1.0 | 0.7 | 0 |
| drug ineffective | 73 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.